This Phase I , open-label , three-period , cross-over pharmacokinetic study enrolled healthy males and females who , following consent and screening procedures , were randomized to receive SJW on days 1-14 , SJW plus boceprevir ( SJW on days 22-35 and together on days 31-35 ) and boceprevir on days 52-56 , separated by 7 day washout periods , or the same treatment in the opposite order .